The agency issues guidance for companies considering registering with FDA as an outsourcing facility.
FDA released guidance on Aug. 11, 2015 directed at companies that are considering registering with the agency as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The guidance is in response to questions the agency received from companies about which activities (e.g., drug compounding) would require a company to register as an outsourcing facility and, therefore, be subject to registration fees.
The FDA guidance gives more information about the regulatory impact of registering as an outsourcing facility, so companies may be better prepared to make the decision to register. FDA issued a separate guidance that details the process for registering.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.